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AbstrAct
Background Combination treatments targeting the 
MEK- ERK pathway and checkpoint inhibitors have 
improved overall survival in melanoma. Resistance to 
treatment especially in the brain remains challenging, and 
rare disease subtypes such as acral melanoma are not 
typically included in trials. Here we present analyses from 
longitudinal sampling of a patient with metastatic acral 
melanoma that became resistant to successive immune 
and targeted therapies.
Methods We performed whole- exome sequencing and 
RNA sequencing on an acral melanoma that progressed 
on successive immune (nivolumab) and targeted 
(dabrafenib) therapy in the brain to identify resistance 
mechanisms. In addition, we performed growth inhibition 
assays, reverse phase protein arrays and immunoblotting 
on patient- derived cell lines using dabrafenib in the 
presence or absence of cerebrospinal fluid (CSF) in vitro. 
Patient- derived xenografts were also developed to analyse 
response to dabrafenib.
Results Immune escape following checkpoint blockade 
was not due to loss of tumour cell recognition by the 
immune system or low neoantigen burden, but was 
associated with distinct changes in the microenvironment. 
Similarly, resistance to targeted therapy was not 
associated with acquired mutations but upregulation of the 
AKT/phospho- inositide 3- kinase pathway in the presence 
of CSF.
Conclusion Heterogeneous tumour interactions within the 
brain microenvironment enable progression on immune 
and targeted therapies and should be targeted in salvage 
treatments.
IntRoduCtIon
The treatment landscape of melanoma 
has changed dramatically in recent years. 
With the advent of combination treatments 
targeting the MEK- ERK pathway and the 
parallel development of immune check-
point inhibitors, patients can now expect to 
survive a median of 36 months with a propor-
tion achieving durable remissions.1 Despite 
these impressive advances, most patients 
treated with these agents still progress and 
die from their disease, and brain metastasis 
in particular remains a persistent clinical 
challenge.2 3 Recent studies have shown that 
although response to targeted and immune 
therapies can be obtained in melanoma brain 
metastases, duration of response is shorter 
than for patients with extracranial disease 
alone.2 4 Understanding of mechanisms of 
resistance is therefore crucial.
Key questions
What is already known about this subject?
 ► Cutaneous melanoma brain metastases have been 
shown to respond to both immune and targeted 
therapies, however response and resistance in acral 
melanoma remains poorly characterised.
 ► The phospho- inositide 3- kinase (PI3K) pathway has 
been shown to be important in the brain, however 
its influence on response to treatment has not pre-
viously been tested using patient- derived models of 
melanoma and specifically acral melanoma brain 
metastases.
What does this study add?
 ► Despite low neoantigen burden, patients with acral 
melanoma can derive benefit from immune therapy. 
Immune therapy escape in the brain was not asso-
ciated with mutational changes, however there was 
decreased infiltration of effector T cells, an increase 
in alternatively activated macrophages and distinct 
changes in gene expression, suggesting the brain 
microenvironment enabled immune escape. In ad-
dition, testing of patient- derived xenografts and cell 
lines showed that resistance to targeted therapy in 
the brain was mediated by extrinsic factors resulting 
in activation of the PI3K/AKT pathway.
How might this impact on clinical practice?
 ► The PI3K/AKT pathway is an important target for 
melanoma brain metastases. Precision medicine 
must address the interactions of the tumour with 
the brain microenvironment and tailor therapies ac-
cording to the site of progression in addition to its 
genomic features.
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Notably, the majority of clinical trials involve patients 
with common cutaneous melanoma and only a small 
number of patients with acral melanoma have been 
included.5 Interrogation of the response of acral mela-
noma to immune and targeted therapies is an important 
aim. Acral melanoma is a rare cutaneous melanoma 
subtype found on non- hair bearing skin such as the 
palms, nail beds and soles,6 and accounts for 2%–3% of 
melanomas.7 The genetic alterations in acral melanoma 
are distinct from those in cutaneous melanoma, with KIT 
mutations more common (15%–20% vs 1%–2%) and 
BRAF mutations less common (15% vs 45%).8 9 Further-
more, acral melanoma is associated with a lower muta-
tional burden and higher copy number variation than 
common cutaneous melanoma.8
We show here that metastatic acral melanoma responds 
to both immune and targeted therapies but, as often seen 
with common cutaneous melanoma, resistance develops 
to both modalities. Through longitudinal sampling of an 
exceptional case of a patient with acral melanoma who 
had isolated progressions in the brain while responding 
in all other sites, first to immune and then to targeted 
therapy, we provide insight into the heterogeneity of 
the tumour microenvironment resulting in resistance 
to standard melanoma treatments. Improved under-
standing of tumour- microenvironment interactions will 
provide hypothesis- driven salvage therapies that target 
the drivers of tumourigenesis, and the distinct tumour 
microenvironments.
MetHods
RnA/dnA extraction
Following microdissection of the tumour to ensure 
tumour purity, RNA/DNA was extracted using the AllPrep 
DNA/RNA Micro Kit (Qiagen) according to manufactur-
er’s instructions. Whole- exome sequencing (WES) and 
RNA- Seq were performed as previously described.10 11
RnA-seq analysis
The RNA- Seq data were aligned to human GRCh37 
assembly by MapSplice (V.2.1.6)12 and further analysis 
performed in R (V.3.1.0). Gene counts were extracted 
using featureCounts13 for Ensembl V.73 annotation 
(V.1.16.1), which were then converted into reads per 
kilobase million (RPKM). The RPKM values are used 
for all expression- level quantification of the genes. 
Genes overexpressed in the brain lesion (log2FC≥2) as 
compared with the baseline lesion were used to perform 
over- representation analysis using the gProfileR package 
(V.0.5.3).14 From the over- representation analysis on 
gene ontology, we represented biological processes in a 
network using Cytoscape.15
Wes analysis
WES data were aligned to human GRCh37 with bwa- mem 
(V.0.7.7).16 Deduplication, realignment and recalibration 
was performed on the aligned data as suggested in the 
Genome Analysis Toolkit (GATK) framework.17 Somatic 
mutation calling was then done using MuTect (V.1.1.7).18
neoantigen determination
Non- synonymous mutations were scanned and candi-
date nonamer peptides identified. The human leukocyte 
antigen (HLA) type of the patient was determined by 
Central Manchester University Hospital (laboratory refer-
ence no 03 GB-009.991) to be HLA A 02:01. Candidate 
sequences were input into NetCTLpan V.1.1 previously 
validated by other groups.19
droplet digital PCR
Each negative control or cell line sample was run over 
three replicate wells. Per well, 10 ng input DNA was 
added to 11 µl ddPCR Supermix for probes (no Uridine-
5'-triphosphate (UTP)) (Bio- Rad) and 0.55 µl of custom 
designed probe (Lifetech) for phospho- inositide 3- kinase 
(PI3K) L25S made up to a total volume of 22 µl with 
water. Droplets were generated using a QX200 automated 
droplet generator (Bio- Rad) and a PCR reaction was 
performed using the following cycling conditions: 95°C 
for 10 min; 40 cycles of 94°C for 30 s and 55°C for 1 min; 
followed by 98°C for 10 min (all at a ramp rate of 2°C/s), 
and a final hold at 4°C (ramp rate 1°C/s). Droplets were 
read using a QX200 droplet reader (Bio- Rad) and the 
data analysed using QuantaSoft software V.1.4.0.99 (Bio- 
Rad).
CIBeRsoRt analysis
The leucocyte signature matrix LM22 (547 genes) that 
differentiates 22 types of tumour- infiltrating immune 
cells was used for the analysis. Normalised gene expres-
sion data from RNA- Seq analysis of each sample (subcu-
taneous and brain lesions) were processed with the Cell 
type Identification By Estimating Relative Subsets Of 
known RNA Transcripts (CIBERSORT) web tool (http:// 
cibersort. stanford. edu/) using default parameters at 100 
permutations.
Cell culture
Cell lines from patient samples were established from 
fresh tumour biopsies, cultured under standard condi-
tions and were routinely monitored for mycoplasma 
contamination by PCR. Cells were cultured in Roswell 
Park Memorial Institute (cell culture media) (RPMI) 
supplemented with 10% fetal bovine serum (FBS) and 
1% penicillin/streptomycin.
short-term growth inhibition assays
Cultured cells from the subcutaneous and brain metas-
tases were seeded into 96- well plates (3000 cells per well). 
Twenty- four hours later, serial dilutions of dabrafenib 
(Selleckchem) were added. Cells were incubated for a 
further 72 hours and viability measured by CellTiter- Glo 
assays (Promega). Relative survival in the presence of 
drugs was normalised to the untreated controls after 
background subtraction. Data from one representative 
experiment are shown.
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Quantification of cell death
Rat cerebrospinal fluid (CSF) was collected as previously 
described.20 Cells were cultured overnight in RPMI or 
50% CSF, treated with dimethyl sulfoxide (DMSO) or 
dabrafenib (1 µM) for 24 hours, then fixed with meth-
anol. Cell death was assessed through blocking with 0.5% 
bovine serum albumin for 1 hour then incubating with 
0.3% cleaved poly (ADP- ribose) polymerase (PARP) 
conjugated with alexa fluor 647 (#6987 Cell Signaling 
Technology) in 0.5% bovine serum albumin for 1 hour 
and acquiring stained cells on an LSR II flow cytometer 
(BD Biosciences). Data of duplicate experiments were 
analysed using FlowJo software V.10.0.8.
twenty-four hours growth inhibition assay in the presence of 
CsF
Cells were cultured overnight under serum- free condi-
tions in RPMI or 50% rat CSF and then treated with 
DMSO, dabrafenib (1 µM), BEZ235 (5 µM) or dabrafenib 
(1 µM) plus BEZ235 (5 µM) (Selleckchem) for 24 hours, 
at which point viability was measured by CellTiter- Glo 
assays (Promega). Relative survival was normalised to 
DMSO controls in either media or in the presence of CSF. 
Data from one representative experiment is shown.
statistical analyses
Unpaired, two- tailed T tests were performed using 
GraphPad Prism software V.7.0a and Microsoft Excel 
V.14.6.9.
Histology and immunohistochemistry
Tumours were formalin- fixed and stained with H&E 
and anti- major histocompatibility complex (MHC) class 
I+HLA A+HLA B antibody (EPR1394Y) (Abcam).
Multiplexing and quantification of immune infiltrate
From each formalin- fixed, paraffin- embedded block, 5 
µm sections were stained with anti- CD4 (MABF750 0.3 
µg/mL), anti- CD8 (M7103 2 µg/mL), anti- CD-163 (NCL- 
CD163 5 µg/mL) and HMB45 (ab732 2 µg/mL). Immu-
nohistochemistry (IHC) was performed on a Ventana 
Discovery Ultra platform. Following deparaffinisation 
and blocking of endogenous peroxidase the antibodies 
were applied sequentially in the order listed. Following 
heat- induced epitope retrieval using cell conditioning 
two (32 mins at 95ᵒ) omnimap antimouse horseradish 
peroxidase (HRP) (760–4310) or omnimap antirabbit 
HRP (760–4311) were used to detect the primaries. 
Following HRP labelling, a Perkin Elmer Opal plex kit 
was used (NEL791001KT). CD4 was labelled with Cy5.5, 
CD8 with fluorescein isothiocyanate (FITC) and HMB45 
(Cy3). A heat step of 8 min (using CC2 at 95ᵒ) was applied 
after each label.
Multiplexed tissue (bright- field and fluorescence) was 
visualised at ×400 total magnification and ×20 image 
fields were acquired. Vectra V.2.0 and Nuance V.2.0 soft-
ware packages (Perkin Elmer, Waltham, Massachusetts, 
USA) were used for automated image acquisition and 
development of the spectral library, respectively. Vectra 
multispectral image files were then converted into multi-
layer Tagged Image File Format (TIFF) format using 
inForm (PerkinElmer, Waltham, Massachusetts) and a 
customised spectral library created. These were converted 
to single layer TIFF files using ImageJ (Fiji). Tumour/
stroma identification and marker quantification were 
performed using Definiens Developer XD (Definiens AG, 
Munich, Germany) and Definiens tissue studio (Definiens 
AG, Munich, Germany).
Cell lysates and immunoblots
Cells were cultured overnight under serum- free condi-
tions in RPMI or 50% rat CSF and then treated with 
DMSO or dabrafenib (1 µM) for 4 hours. Cell lysates were 
prepared with Nonidet™ P40 (NP40) buffer containing 
5% ß-mercaptoethanol, 150 mM NaCl, 50 mM Tris pH 
7.5, 2 mM EDTA pH 8, 25 mM sodium fluoride (NaF) 
and 1% NP40, protease inhibitors (Complete, Roche), 
phosphatase inhibitor cocktails II and III (Sigma). All 
lysates were freshly prepared and resolved by SDS gel 
electrophoresis for western blotting. Primary antibodies 
were: p44/42 mitogen- activated protein kinase (MAPK) 
(Erk1/2) (137F5) (Cell Signaling Technology) p- ERK1/2 
(MAPK- YT) (Sigma Aldrich), AKT1 (2H10), phospho- 
protein kinase B (pAKT) (S473) and pAKT (T308, 
244F9) (Cell Signaling Technology). Specific bands were 
detected using fluorescent- labelled secondary antibodies 
(Invitrogen; LI- COR Biosciences) and analysed using an 
Odyssey infrared scanner (LI- COR Biosciences). Immu-
noblots were performed in duplicate.
Reverse phase protein array
Cells were cultured overnight under serum- free condi-
tions in RPMI or 50% rat CSF and then treated with 
DMSO or dabrafenib (1 µM) for 4 hours. Lysates were 
freshly prepared and fluorescence based nitrocellulose 
reverse phase protein array (RPPA) was performed as 
previously described.21
Collection of patient samples
Patient samples were collected with written, fully informed 
patient consent under Manchester Cancer Research 
Centre (MCRC) Biobank ethics application #07/
H1003/161+5 and approval for the work under MCRC 
Biobank Access Committee application 13_RIMA_01.
Animal procedures
All procedures involving animals were performed in 
accordance with National Home Office regulations 
under the Animals (Scientific Procedures) Act 1986 and 
within guidelines set out by the Cancer Research UK, 
MI Manchester Institute (CRUK MI's) Animal Welfare 
and Ethical Review Board, carried out under license 
PPLPE3DF1A5B (formerly PPL70/7701), and reported 
in accordance with ARRIVE guidelines. Mice were main-
tained in pathogen- free, ventilated cages in the Biological 
Resources Unit at CRUK MI with free access to irradiated 
food and autoclaved water in a 12- hour light/dark cycle, 
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with room temperature at 21±2°C. Cages contained wood 
shavings, bedding and a cardboard tube. All procedures 
were conducted in the light phase.
establishing and dosing of patient-derived xenografts
Patient tumour samples (~80 mm3) were implanted 
subcutaneously in flanks of 6- week- old female NOD scid 
gamma (NSG) mice. These were expanded in a further 
passage of mice and experiments performed in passage 
3. Animals were dosed by daily orogastric gavage with 
dabrafenib (Selleckchem) 25 mg/kg or vehicle (5% 
DMSO in water). For the subcutaneous lesion, 14 animals 
were randomised when tumours were between 50 mm3 
and 120 mm3 into groups receiving dabrafenib or vehicle 
for up to 40 days. For the brain lesion, 20 animals were 
randomised on a rolling recruitment basis when tumours 
reached 50–120 mm3 into groups receiving dabrafenib or 
vehicle for up to 38 days. Tumour volume was determined 
by calliper measurements of tumour length (L), width 
(W) and depth (D), and calculated as volume=L×W×D× 
 pi /6, measured from the day treatment commenced until 
volume approached 1500 mm3 or the mouse was eutha-
nised for welfare reasons.
Results
neoepitope expression, IFnγ signalling and antigen 
processing are conserved in the brain lesion that had escaped 
immune-surveillance
We describe a patient in their early 40s who presented 
acral melanoma on the sole of the right foot (figure 1A, 
green lesion). The tumour was resected, but recurred at 
the original scar site 2 years later and was again removed. 
A year later, the patient developed widespread disease, 
with a subcutaneous lesion in the right thigh, and several 
metastases in the hilar lymph nodes, liver and lungs 
(figure 1A). To alleviate clinical symptoms, the subcuta-
neous thigh tumour was resected, providing a pretreat-
ment baseline sample. The other lesions were inoperable, 
so nivolumab (3 mg/kg every 2 weeks) was administered 
and the patient achieved an excellent response for M1c 
disease, with disappearance of all of the tumours in the 
hilum, liver and lung. These tumours did not return, 
but despite this remarkable ongoing systemic response, 
an isolated lesion in a mediastinal lymph node slowly 
progressed and 7 months after starting nivolumab was 
confirmed to be PET- positive. This immune- refractory 
lesion was resected, and imaging confirmed the patient 
was disease- free and continued to respond to nivolumab. 
Unfortunately, despite the excellent ongoing response, 
after 12 months the patient developed grade 3 diarrhoea, 
necessitating nivolumab withdrawal. Within a month, the 
patient presented with neurological symptoms at another 
hospital and MRI scan revealed a new solitary metastasis 
in the brain that was resected (figure 1A).
The thigh resection provided a baseline pretreatment 
tumour from a patient who presented a complete response 
to nivolumab, and the brain lesion provided a tumour 
that had escaped the immune control normally associ-
ated with complete response to checkpoint blockade.22 
Notably, MHC class I proteins remained highly expressed 
in the immune- escape brain tumour (figure 1B), and 
melanoma associated antigen gene expression was also 
unaltered (online supplementary fig. 1). Thus, the 
immune escape in this patient’s brain metastasis was not 
mediated by changes in antigen presentation or loss of 
melanoma antigens.
Consistent with previous studies in acral melanoma,8 
WES revealed a very low mutation burden, with 25 non- 
synonymous single nucleotide variants (SNVs) in the 
baseline tumour and 27 in the brain metastasis (figure 1C; 
online supplementary table 1). Twenty- four of these 
SNVs were shared mutations, revealing low genomic 
heterogeneity (figure 1C) and only five mutations (SACS, 
PHOX2B, UGT8, CLEC10A, SCL16A13) were predicted to 
generate high affinity MHC class I epitopes for cytotoxic 
T lymphocytes (online supplementary table 2). RNA- Seq 
revealed that expression of these genes did not decrease 
in the brain lesion (figure 1D). Moreover, all five candi-
date neoantigens were expressed at low levels in the base-
line and immune- escape tumour (<5 RPKM; figure 1D, 
online supplementary table 2). Thus, immune escape 
was unlikely to have been mediated by loss of neoantigen 
expression, and we did not observe mutations in JAK2 or 
related genes, which drive immune therapy resistance 
through interferon gamma (IFNγ) signalling or muta-
tions resulting in loss of PTEN, which has been shown to 
result in immunosuppression.23–25
nivolumab resistance is associated with a distinct gene 
signature and immune infiltrate
To investigate underlying mechanisms, we examined 
gene expression in microdissected tumour samples (to 
ensure tumour purity) from the lesions. We used biolog-
ical processes and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway analyses of RNA- Seq expres-
sion data to reveal differences between the baseline and 
immune- escape brain metastasis. This showed that biolog-
ical processes such as cytokine- secretion, type 2 immune 
response and chemokine- mediated signalling were signif-
icantly upregulated in the resistant lesion (figure 1E, 
online supplementary figure 2, online supplementary 
table 3). We did not observe a signature associated with 
loss of PTEN as previously described (online supple-
mentary table 4),24 25 and neither was there evidence of 
increased activation of Wnt/ß-catenin and downregula-
tion of chemokines associated with increased Wnt/ß-cat-
enin expression leading to resistance to anti- programmed 
death-1 (PD-1) therapy (online supplementary table 5).26 
Although there was an increase in expression of genes 
associated with many inflammatory factors, there was 
particularly high expression in the brain metastasis of 
CXCL1 and IL10 which are involved in tumour progres-
sion, immune tolerance and infiltration of immunosup-
pressive cells (figure 1E).27–29
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Figure 1 Immune escape in the brain is associated with a distinct microenvironment. (A) Timeline of patient’s clinical 
history. Green font, response; red font, progressive disease; grey font, toxicity; CR, complete response; PR, partial response; 
P, PDX; C, cell line; XRT, whole brain radiotherapy, red lesions are areas sampled, purple lesions sites of disease spread, 
green lesion primary site. Subcut., subcutaneous metastasis. (B) MHC class I expression is conserved in the immune- 
escape lesion compared with baseline lesion. Immunohistochemistry showing MHC class I expression in the baseline and 
immune- escape lesions. Scale bar, 20 µM. (C) The patient’s tumours have a low mutation burden. Venn diagram showing 
distribution of non- synonymous mutations identified by WES in the baseline (Subcut.) and immune- escape (Brain) lesions. 
(D) Neoantigens expression is unaltered in the baseline and immune- escape melanomas. Mutations identified through whole- 
exome sequencing (WES) were analysed using NetCTL and predicted neoantigens with a high affinity for MHC class I binding 
(score <1) are depicted. In shaded blue, the gene expression (reads per kilobase per million; RPKM) of the mutated genes 
present in the baseline (Subcut.) and immune- escape (Brain) lesions. (E) Nivolumab resistance is associated with upregulation 
of genes related to immunity. Supervised clustering of RNA- Seq data for selected genes associated with tumour- immune 
interaction of the baseline and immune escape brain lesion. Z- score (SD from the mean) depicted in blue, downregulated; 
red, upregulated. Log2FC, log2 fold change of the expression values (brain lesion/subcutaneous lesion) is represented in blue- 
yellow- red gradient. (F) Immune- escape is associated with decreased T cell infiltration. Example photomicrograph images 
depicting heterogeneous composition of immune cell infiltrates within tumour and stroma. Left panel is overlay of the four 
different markers: green, CD4+; orange, CD8+; purple, CD163+; cyan, HMB45. Quantification (mean and SD) for multiple 
panels of immune cell infiltrate in each lesion using Definiens is below each representative panel. NS, not significant; *p<0.05; 
**p<0.01; ***p<0.001. (G) Immune- escape is associated with heterogeneous immune cell infiltration using CIBERSORT. Bar 
chart summarising immune cell subset proportion of 22 types of adaptive and innate immune cells quantified by CIBERSORT 
for the three lesions. (H) Immune- escape is associated with altered expression of immunomodulatory genes. Gene expression 
of immunomodulators quantified in the baseline (Subcut.) and immune- escape (Brain) lesions based on RNA- Seq analysis.
Thus, compared with the baseline, the immune- escape 
tumour presented a distinct gene signature, so we exam-
ined immune cell infiltrates in these lesions by multiplex 
IHC. This revealed a trend towards higher CD4+ and 
CD163+ infiltrate in the brain metastasis in both tumour 
and stromal areas compared with the subcutaneous lesion 
(figure 1F). Critically, CD8+ infiltrate was significantly 
decreased in the brain lesion tumour area compared with 
both its surrounding stroma and also compared with the 
tumour area of the subcutaneous lesion (figure 1F).
We performed CIBERSORT30 to further examine the 
immune cell infiltrate. This revealed that the subcutaneous 
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Figure 2 Brain lesions retain dabrafenib sensitivity outside the brain microenvironment. (A) CT images of patient’s brain 
lesion and paraoesophageal lesion in response to dabrafenib. Left CT images show predabrafenib (brain lesion measuring 
1×0.9 cm), middle images show partial response to dabrafenib (brain lesion measuring 0.9×0.5 cm) and right images show 
disease progression in the brain (brain lesion measuring 2.1×1.7 cm) and ongoing response in extracranial sites on dabrafenib. 
(B) Cells derived from the dabrafenib- resistant brain lesion remain sensitive to dabrafenib in vitro. Short- term growth inhibition 
assays (72 hours) of cells from the subcutaneous metastasis (GI50 0.001 µM) and a brain metastasis (GI50 0.002 µM) grown in 
the presence of dabrafenib (0.15 nM to 1 µM). (C, D) PDX derived from the subcutaneous and brain lesions are both sensitive 
to dabrafenib when grown outside of the brain in vivo. Mice were treated with dabrafenib (25 mg/kg/day) or vehicle by oral 
gavage. Drug treatments commenced immediately after tumours reached 50–120 mm3 and show individual tumour volumes 
(n=7–11 per group).
lesion had a higher presence of M0 macrophages, while 
the brain lesion presented a higher proportion of alterna-
tively activated (M2) macrophages and regulatory T cells, 
which are immunosuppressive and have been linked to 
the lack of response to anti- PD-1 therapy (figure 1G).31 32 
Finally, the brain metastasis also presented mRNA upreg-
ulation of immunomodulators such as TIM3 and LAG3, 
which are associated with T cell exhaustion,33 and thereby 
tumour escape from the immune system (figure 1H). 
Thus, the immune- escape brain lesion was associated with 
a general increase in inflammation and negative immune 
mediators with infiltrate of cells associated with immu-
nosuppression and decrease infiltrate of effector T cells 
compared with the pretreatment subcutaneous lesion.
Resistance to targeted therapy in the brain
Following resection of the brain lesion, the patient 
received whole brain radiation, but progressed within 
3 months with regrowth of the brain tumour, and the 
appearance of a new paraoesophageal lymph node 
tumour (figure 1A). As the patient’s tumour harboured 
a p.V600E BRAF mutation, dabrafenib was administered 
and the patient achieved resolution of the lymph node 
lesion and a partial response in the brain (50% decrease). 
Intriguingly, despite an ongoing extracranial response to 
dabrafenib, after 3 months the brain lesion progressed 
and was resected (figure 2A). The patient continued on 
dabrafenib, but the brain metastasis progressed after 
a further 4 months and was once again resected. The 
patient remained stable on dabrafenib until progression 
2 months later, when tumour infiltrating lymphocyte 
(TIL) therapy was administered, but the patient passed 
away shortly after.
We developed a patient- derived xenograft from the 
pre dabrafenib brain lesion, and a cell line from the 
progressing brain lesion and used those to determine 
how dabrafenib resistance in the brain was mediated. 
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Notably, cells from both the baseline subcutaneous, and 
the dabrafenib- resistant brain lesion displayed similar 
sensitivity to dabrafenib in vitro (figure 2B). Similarly, 
patient- derived xenograft (PDX) from the two sites were 
equally sensitive to dabrafenib when grown in the flank 
of immunocompromised mice (figure 2C,D). Consis-
tent with these results, WES of a cell line derived from 
the progressing brain metastasis did not reveal any muta-
tions such as an activating mutation in NRAS, that could 
explain resistance to dabrafenib (a L25S PIK3CA muta-
tion outside of the binding domain was associated with 
strand bias and was not confirmed by droplet digital PCR; 
online supplementary tables 7 and 8).
In line with other clinical responses,2 34 the initial 
response of the brain lesion to dabrafenib suggested 
that the drug did cross the blood- brain barrier, and our 
data suggest that resistance was not mediated by cell- 
intrinsic events, so we examined if resistance was medi-
ated by factors in the brain microenvironment. Cells were 
grown in serum- free medium for 24 hours in the pres-
ence or absence of dabrafenib, with or without rat CSF. 
Dabrafenib inhibited growth, and induced apoptosis in 
cells derived from the resistant tumour, but consistent 
with a recent report,20 in the presence of CSF the cells 
overcame both the growth inhibition and induction of 
apoptosis mediated by dabrafenib (figure 3A,B).
Intriguingly, despite rescuing proliferation and survival, 
the presence of CSF did not result in reactivation of ERK 
in the cells from the resistant lesion (figure 3C), so we 
used RPPA to identify which pathways were activated. 
This confirmed that CSF did not reactivate MEK/ERK 
signalling (figure 3D,E), and also that downstream S6 
phosphorylation35 was not reactivated (figure 3F,G). 
However, the RPPA analysis revealed increased protein 
kinase B (PKB, aka AKT) phosphorylation (figure 3H,I) 
in the presence of CSF, suggesting that CSF induced resis-
tance through the PI3K signalling pathway rather than 
alternative pathways investigated in the RPPA screen. 
In addition, we observed increased phosphorylation of 
the platelet- derived growth- factor receptor (PDGFR), 
which is known to activate PI3K/AKT signalling, whereas 
phosphorylation of other receptor tyrosine kinases was 
not increased (figure 3J, online supplementary table 
9). We confirmed increased PI3K/AKT signalling in the 
presence of CSF in the cell line from the subcutaneous 
metastasis (online supplementary fig 3A- F), supporting 
an extrinsic cause for PI3K/AKT activation rather than 
an intrinsic cause such as a newly acquired mutation in 
the brain lesion cells. In addition, immunoblot showed 
an increase in AKT phosphorylation in the presence of 
CSF with and without dabrafenib (figure 3K). Accord-
ingly, in standard media whereas dabrafenib inhibited 
the growth of the brain lesions cells, the PI3K/mamma-
lian target of rapamycin (mTOR) inhibitor BEZ235 was 
without effect (figure 3L). Conversely, in the presence of 
CSF, dabrafenib no longer inhibited the growth of the 
brain lesion cells, whereas BEZ235 inhibited the growth 
of these cells (figure 3L). The switch in growth inhibition 
from dabrafenib to BEZ235 is consistent with rewired 
signalling from dependence on BRAF- ERK signalling in 
normal medium to dependence on PI3K signalling in 
CSF.
dIsCussIon
Recent studies have reported that immune therapy 
responses are associated with high mutation and neoan-
tigen burden and low intratumorous heterogeneity.36 37 
Typical for acral melanoma,8 the tumours presented here 
had low mutation and neoantigen burden, but despite 
this the patient responded to nivolumab for 12 months 
and was only removed from treatment due to toxicity. Our 
data therefore show that clinical benefit can be achieved 
by immune therapy in tumours that present with low 
mutation and neoantigen burden. This is in line with 
clinical studies showing that acral melanoma responses to 
immune therapy are similar to those of cutaneous mela-
noma.5 We therefore caution against excluding patients 
from immune therapies solely due to low mutation 
burden and consequent low neoantigen load.
The patient initially mounted an impressive antitumour 
response on nivolumab with shrinkage of all lesions. 
However, resection of the progressing brain lesion 
following complete response provided a rare opportunity 
to study paired lesions, one of which escaped the immune 
system following checkpoint blockade. We did not find 
significant changes in neoantigen or MHC class I expres-
sion and did not discover mutations that would impair 
PTEN, IFNγ or similar signalling pathways, which can 
drive resistance to immune therapies.23 25 38 39
Notably, the brain lesion presented a gene signature and 
immune infiltrate associated with a significantly different 
microenvironment to the subcutaneous lesion. RNA- 
Seq data suggested increased infiltration into the brain 
metastasis of T regulatory cells and M2 macrophages and 
increased expression of genes encoding CXCL1 and IL10 
was seen, which are associated with immunosuppression 
and an immunosuppressive infiltrate.27–29 Finally, tran-
scripts associated with checkpoints expressed on tumour 
infiltrating T cells such as TIM3 and LAG3, which are 
markers of T cell exhaustion and immune therapy resis-
tance, were increased in the brain metastasis compared 
with the subcutaneous lesion.33 Critically, the brain metas-
tasis was associated with significantly lower CD8+ effector 
T cell infiltration compared with the surrounding stroma, 
a pattern not seen in the baseline subcutaneous lesion. 
Decreased T cell infiltration has also been reported in 
cutaneous melanoma brain metastases compared with 
extracranial biopsy sites.40
Thus, immune escape did not appear to be driven by 
loss of the intrinsic ability of T cells to recognise and kill 
the tumour cells, but by the acquisition of a distinct micro-
environment. This highlights the need to develop person-
alised medicine approaches that incorporate targeting 
of heterogeneous microenvironments particularly for 
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Figure 3 Cerebrospinal fluid (CSF) mediates resistance to dabrafenib through the PDGFR/PI3K/Akt pathway. (A) CSF 
overcomes dabrafenib- induced cell growth inhibition. Short- term growth assays showing cell growth after 24 hours following 
treatment with DMSO or dabrafenib (Dab; 1 µM) in RPMI or 50% CSF using CellTiter- Glo ****p<0.0001; NS, not significant. 
(B) CSF overcomes dabrafenib- induced cell death. Cells were cultured overnight under serum- free conditions in RPMI or 
50% CSF and then treated with DMSO or dabrafenib (Dab; 1 µM) for 24 hours before assessing cell death using cleaved 
PARP staining measured by flow cytometry. ***p<0.001; NS, not significant. (C) CSF does not rescue MEK/ERK signalling in 
dabrafenib- treated cells. Cells were plated and incubated overnight in RPMI or 50% CSF under serum- free conditions before 
treatment of DMSO or dabrafenib 1 µM for 4 hours. Immunoblot analysis shows phosphoERK Thr202/185 Tyr204/187 and ERK 1/2. 
Tubulin was used as a loading control. (D–J) CSF rescue of cell growth correlates with PDGFR/PI3K/AKT pathway activation. 
Cells from the brain metastasis were incubated overnight in RPMI or 50% CSF under serum- free conditions before treatment 
of DMSO or dabrafenib 1 µM for 4 hours. Cell lysates were obtained and fluorescence- based nitrocellulose reverse phase 
protein array (RPPA) was performed for phospho- MEK1/2 (D), phospho- ERK (E), phospho- S6 (F, G), phospho- AKT (H, I), 
phospho- PDGFR (J), *p<0.05, **p<0.01, ****p<0.0001. (K) CSF induces AKT phosphorylation. Cells from the brain metastasis 
were incubated overnight in RPMI or 50% CSF under serum- free conditions before treatment of DMSO or dabrafenib 1 µM for 
4 hours. Immunoblot analysis shows phospho AKTT308/S473 and AKT1. Tubulin was used as a loading control. (L) PI3K/MTOR 
inhibition reduces cell growth in the presence of CSF. Graph showing cell growth measured by CellTiter- Glo 24 hours after 
treatment with DMSO, dabrafenib (Dab 1 µM), BEZ235 (BEZ 5 µM) or dabrafenib (Dab 1 µM) plus BEZ235 (BEZ 5 µM) in RPMI 
or 50% CSF under serum- free conditions. **p<0.01; ***p<0.001; NS, not significant; PDGFR, platelet- derived growth- factor 
receptor; PI3K, phospho- inositide 3- kinase.
patients with brain metastases or brain progression on 
immunotherapy.
Despite surgery and radiotherapy, the brain lesion 
progressed necessitating treatment with dabrafenib. 
Initially, the patient mounted an excellent response, and 
in accordance with the BREAK- MB Trial,34 this included 
a shrinkage of the brain lesion. However, despite a 
continued extracranial response, the brain lesion relapsed 
rapidly. We did not find new mutations to explain resis-
tance, and cells from the dabrafenib- resistant brain lesion 
remained sensitive to dabrafenib in vitro, as did the PDX 
derived from the pretreatment brain metastasis in the 
flank of immunocompromised mice. In accordance with 
a study by Seifert et al,20 we found that CSF overcame the 
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antiproliferative and proapoptotic effects of dabrafenib 
on cells from the cranial lesion. Notably, rescue of cell 
growth by CSF was not accompanied by mitogen- activated 
protein kinase kinase - extracellular signal- regulated 
kinase (MEK- ERK) pathway reactivation, but by hyperac-
tivation of the PI3K/AKT pathway. The same effect was 
seen in cells from the subcutaneous metastasis suggesting 
an extrinsic rather than intrinsic cause for the dabrafenib 
resistance. Unfortunately, due to the limited tissue avail-
able we were unable to confirm increased phosphoryla-
tion of protein kinase B (AKT) in the brain lesion by IHC. 
However, a PI3K/mTOR inhibitor significantly reduced 
proliferation of the cells in the presence of CSF, but had 
little effect on cells in media alone. This is consistent 
with findings from a study, which showed that a pan- PI3K 
inhibitor suppressed the growth of melanoma cells both 
in astrocyte- conditioned media and in the brains of nude 
mice.41
Thus, we show here that progression on immune and 
targeted therapies could be mediated by interactions 
between the tumour and brain microenvironment. In 
the case of immune therapy, immune escape was associ-
ated with a heterogeneous immune infiltrate and gene 
expression profile compared with the baseline lesion, 
whereas CSF factors contributed to resistance to targeted 
therapy through the PI3K/AKT pathway. The brain is a 
common site of treatment failure in many cancers and 
this site continues to be a challenge in the era of immune 
and targeted therapies in melanoma. However, patients 
with brain metastases are often excluded from clinical 
trials and their optimal management remains uncertain. 
Our study provides insight into the importance of the 
microenvironment in mediating resistance and we show 
that improved knowledge of underlying mechanisms can 
provide hypothesis- driven salvage treatment strategies. 
Thus, both mutational characteristics and the site- specific 
microenvironment characteristics of individual mela-
noma lesions need to be considered to optimise precision 
medicine strategies for patients with melanoma.
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